Innovative device tackles racial bias in health monitoring, ensuring accurate readings for all skin tones In 2022, original research published in BMJ Innovations introduced a pioneering non-invasive device that corrects racial bias in haemoglobin and pulse oximetry measurements. The paper, “Innovative technology to eliminate the racial bias in noninvasive, point-of-care (POC) haemoglobin and pulse oximetry measurements” , revealed the first ever technology that integrates green light and skin melanin quantification into noninvasive oximetry and haemoglobin measurement. Designed for use at home, in clinics, and critical care settings, it offers a scalable, accessible solution that could reduce health disparities in oxygen monitoring, addressing longstanding inaccuracies in existing devices. Beyond improving diagnostic accuracy, this technology could potentially drive significant change in health equity, particularly in settings with limited resources and underserved communities. This research is not only advancing science, it is shaping a more equitable future in health technology.
Research with real world impact
Health equity: Offers a transformative solution for underserved and resource poor settings, helping reduce racial disparities in diagnostic accuracy Global recognition: Accepted for presentation at the UNICEF/SAARC International Conference in Sri Lanka Academic endorsement: Attracted direct interest from Cornell University, NYC Funding success: Publication supported successful bid for prestigious NIH Phase 2 clinical study grant Global collaboration: Catalysed partnerships with leading researchers and institutions, accelerating technology development Research visibility: Cited 10 times in two years; six times higher than the field average Career progression: Led to mentorship opportunities and a research faculty position for Dr Gokhale Award recognition: Winner of the Anaemia Innovation Challenge for its breakthrough in non- invasive haemoglobin measurement
“The publication in BMJ Innovations has sparked an unprecedented level of attention and conversation. Key stakeholders like the US Food and Drug Administration, policymakers, and device developers are now taking serious note of this unmet need.” Dr Sanjay Gokhale , medical scientist and chief executive officer of Shani Biotechnologies, Texas, USA
Powered by FlippingBook